OLFM4

Across TCGA pan-cancer cohorts, OLFM4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OLFM4 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher OLFM4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated OLFM4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where OLFM4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.260	0.638	.001	36	view →
CCRCC	OS	Median	IV	0.785	0.123	.009	18	view →
LUAD	OS	Median	III,IV	0.206	0.684	.002	12	view →
HNSC	DFS	Median	II,III,IV	0.975	0.900	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

OLFM4–PDAC (OS)

Open the PDAC breakdown →